Bausch + Lomb Corp

NYSE:BLCOUnited StatesView on Canadian Exchange

Today

Show headlines and story abstract

• Bausch + Lomb Announces Presentation of New Scientific Data and Evaluations Featuring Consumer, Vision Care and Pharmaceutical Products at Optometry's Meeting(R), from 2 hours ago by Business Wire

  2 hours ago by Business Wire
  Companies Mentioned: BLCO

  Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of 12 ePosters during the American Optometric Association (AOA) Optometry's Meeting ePoster Session, taking place virtually May 29-30, 2024. The company will also have three live presentations and host nine education events during the in-person meeting, taking place in Nashville June 19-22, 2024.

• Bausch + Lomb Announces Presentation of New Scientific Data and Evaluations Featuring Consumer, Vision Care and Pharmaceutical Products at Optometry's Meeting(R), from 2 hours ago by Dow Jones

  2 hours ago by Dow Jones
  Companies Mentioned: BLCO
  
  IMPORTANT SAFETY INFORMATION
  -- LOTEMAX SM, as with other ophthalmic corticosteroids, is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. -- Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. If LOTEMAX SM is used for 10 days or longer, IOP should be monitored. -- Use of corticosteroids may result in posterior subcapsular cataract formation. -- The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation. In those with diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification such as slit lamp biomicroscopy and, where appropriate, fluorescein staining. -- Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, steroids may mask infection or enhance existing infections. -- Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). -- Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal cultures should be taken when appropriate. -- Contact lenses should not be worn when the eyes are inflamed. -- There were no treatment-emergent adverse drug reactions that occurred in more than 1% of subjects in the three times daily group compared to vehicle.
  

• Bausch + Lomb's New Intraocular Lens Approved by Health Canada, from 2 hours ago by MT Newswires

  2 hours ago by MT Newswires
  Companies Mentioned: BLCO
  08:15 AM EDT, 05/28/2024 (MT Newswires) -- Bausch + Lomb (BLCO) said Tuesday that Health Canada has approved its enVista Envy full visual range intraocular lens. The company said it plans to introduce additional designs in the coming months to expan...

• -- Bausch + Lomb Brief: Says Received Health Canada Approval for Full Visual Range Intraocular Lens, from 4 hours ago by MT Newswires

  4 hours ago by MT Newswires
  Companies Mentioned: BHC, BLCO
  06:59 AM EDT, 05/28/2024 (MT Newswires) -- ...

• Bausch + Lomb Receives Health Canada Approval for enVista(R) Envy(TM)* Full Visual Range Intraocular Lens, from 4 hours ago by Business Wire

  4 hours ago by Business Wire
  Companies Mentioned: BLCO

  Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Health Canada has approved the enVista(R) Envy(TM)* full visual range intraocular lens (IOL). This is the first global regulatory approval of the new lens, which offers a full range of vision with excellent dysphotopsia tolerance on the widely used enVista IOL platform.